| Literature DB >> 31325411 |
Zekai Chen1,2, Guanzhi Chen3, Hailun Qin1,2, Zefeng Cai1,2, Jianhuan Huang1,2, Haojia Chen1,2, Weiqiang Wu2, Zhichao Chen2, Shouling Wu4, Youren Chen2.
Abstract
AIMS/Entities:
Keywords: Cardiovascular risks; Chinese; Triglyceride to high-density lipoprotein cholesterol ratio
Mesh:
Substances:
Year: 2019 PMID: 31325411 PMCID: PMC7078082 DOI: 10.1111/jdi.13118
Source DB: PubMed Journal: J Diabetes Investig ISSN: 2040-1116 Impact factor: 4.232
Baseline characteristics of 96,542 participants of the Kailuan Study
| Characteristics | All participants | TG/HDL‐C ratio |
| |
|---|---|---|---|---|
| Low ≤0.8533 | High >0.8533 | |||
|
| 96,542 | 48,567 (50.3) | 47,975 (49.7) | – |
| Age (years) | 51.5 ± 12.6 | 51.4 ± 13.1 | 51.6 ± 12.0 | 0.154 |
| Male, | 76,854 (79.6) | 37,140 (76.5) | 39,714 (82.8) | <0.001 |
| Education ≥high school, | 18,803 (19.5) | 9,650 (19.9) | 9,153 (19.1) | 0.002 |
| Heart rate (b.p.m.) | 73.8 ± 10.2 | 73.2 ± 10.1 | 74.4 ± 10.2 | <0.001 |
| BMI (kg/m2) | 25.0 ± 3.5 | 24.1 ± 3.3 | 26.0 ± 3.4 | <0.001 |
| SBP (mmHg) | 130.7 ± 20.9 | 128.3 ± 20.8 | 133.1 ± 20.7 | <0.001 |
| DBP (mmHg) | 83.4 ± 11.8 | 81.7 ± 11.5 | 85.1 ± 11.8 | <0.001 |
| FPG (mmol/L) | 5.47 ± 1.67 | 5.27 ± 1.40 | 5.67 ± 1.87 | <0.001 |
| HDL‐C (mmol/L) | 1.55 ± 0.40 | 1.68 ± 0.41 | 1.41 ± 0.35 | <0.001 |
| LDL‐C (mmol/L) | 2.34 ± 0.91 | 2.31 ± 0.90 | 2.38 ± 0.93 | <0.001 |
| TC (mmol/L) | 4.94 ± 1.14 | 4.90 ± 1.00 | 4.99 ± 1.27 | <0.001 |
| TG (mmol/L) | 1.27 (0.89–1.92) | 0.90 (0.70–1.12) | 1.92 (1.48–2.78) | <0.001 |
| hs‐CRP (mmol/L) | 0.80 (0.30–2.18) | 0.70 (0.25–1.94) | 0.94 (0.37–2.40) | <0.001 |
| Current drinker, | 16,804 (17.4) | 8,197 (16.9) | 8607 (17.9) | 0.005 |
| Current smoker, | 32,164 (33.3) | 15,060 (31.0) | 17,104 (35.7) | <0.001 |
| Physical activity, | 14,037 (14.5) | 6,994 (14.4) | 7,043 (14.7) | 0.218 |
| Hypertension, | 41,790 (43.3) | 18,224 (37.5) | 23,566 (49.1) | <0.001 |
| Diabetes, | 8,728 (9.0) | 2,950 (6.1) | 5,778 (12.0) | <0.001 |
| Antidiabetic drug therapy, | 2,066 (2.14) | 755 (1.55) | 1,311 (2.73) | <0.001 |
| Antihypertensive drug therapy, | 8,753 (9.07) | 3,270 (6.73) | 5,483 (11.43) | <0.001 |
Continuous variables were described by mean ± standard deviation (normal distribution)/median (quartile) (abnormal distribution); categorical variables were presented by number (percentage). The ranges in parentheses represence median (quartile). BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL‐C, high‐density lipoprotein cholesterol; hs‐CRP, high sensitivity C‐reactive protein; LDL‐C, low‐density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride.
Incidence rate of adverse outcomes stratified by the triglyceride to high‐density lipoprotein cholesterol ratio
| Group |
| No. CV events | Cumulative incidence (95% CI) | Per 100,000 person‐years |
|---|---|---|---|---|
| Total CV events | ||||
| Total | 96,542 | 5,422 | 5.62 (5.47–5.76) | 576.02 |
| Low TG/HDL‐C ratio group | 48,567 | 2,307 | 2.39 (2.29–2.49) | 485.20 |
| High TG/HDL‐C ratio group | 47,975 | 3,115 | 3.23 (3.12–3.34) | 668.00 |
|
| – | – | <0.001 | – |
| Stroke | ||||
| Total | 96,542 | 4,228 | 4.38 (4.25–4.51) | 445.97 |
| Low TG/HDL‐C ratio group | 48,567 | 1,856 | 1.92 (1.84–2.01) | 388.76 |
| High TG/HDL‐C ratio group | 47,975 | 2,372 | 2.46 (2.36–2.55) | 504.51 |
|
| – | – | <0.001 | – |
| MI | ||||
| Total | 96,542 | 1,312 | 1.36 (1.29–1.43) | 136.45 |
| Low TG/HDL‐C ratio group | 48,567 | 493 | 0.51 (0.47–0.56) | 101.92 |
| High TG/HDL‐C ratio group | 47,975 | 819 | 0.85 (0.79–0.91) | 171.57 |
|
| – | – | <0.001 | – |
CI, confidence interval; CV, cardiovascular; MI, myocardial infarction; TG/HDL‐C, triglyceride to high‐density lipoprotein cholesterol.
Hazard ratios of major cardiovascular events
| Group | Model 1 | Model 2 | Model 3 |
|---|---|---|---|
| Total CV events | |||
| Low TG/HDL‐C ratio group | 1 | 1 | 1 |
| High TG/HDL‐C ratio group | 1.37 (1.30–1.45) | 1.41 (1.33–1.48) | 1.19 (1.12–1.26) |
| Stroke | |||
| Low TG/HDL‐C ratio group | 1 | 1 | 1 |
| High TG/HDL‐C ratio group | 1.30 (1.22–1.38) | 1.32 (1.24–1.41) | 1.11 (1.03–1.18) |
| MI | |||
| Low TG/HDL‐C ratio group | 1 | 1 | 1 |
| High TG/HDL‐C ratio group | 1.68 (1.51–1.88) | 1.73 (1.55–1.94) | 1.50 (1.33–1.70) |
Model 1 was stratified for the triglyceride to high‐density lipoprotein cholesterol (TG‐HDL‐C) ratio; model 2 was further adjusted for age and sex; model 3 further adjusted for smoking status, alcohol consumption, education, physical exercise, diabetes, hypertension, total cholesterol, low‐density lipoprotein cholesterol, heart rate, high sensitivity C‐reactive protein, body mass index, antidiabetic drug therapy, antihypertensive drug therapy. The values in parentheses represented by HR (95% CI). CV, cardiovascular; MI, myocardial infarction.
Figure 1The association between the triglyceride to high‐density lipoprotein cholesterol (TG/HDL‐C) ratio and total cardiovascular events.
Figure 2The association between the triglyceride to high‐density lipoprotein cholesterol (TG/HDL‐C) ratio and stroke.
Figure 3The association between the triglyceride to high‐density lipoprotein cholesterol (TG/HDL‐C) ratio and total myocardial infarction.